TCRT Alaunos Therapeutics, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1107421 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-50.0%
TTM net income YoY10.0%
TTM EPS YoY39.1%
Revenue 3-yr CAGR-41.5%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-121,033.3%
Net margin-120,766.7%
FCF margin—
EBITDA margin-119,966.7%
Returns
ROE-192.0%
ROA-128.4%
ROIC (approx.)-469.9%
Asset turnover0.00x
Leverage & solvency
Liabilities / assets49.4%
Debt / equity0.00x
Current ratio1.14x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.64x
Accruals ratio-46.6%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $0 | $0 | $0 | $3,000 | $0 | $0 | $2,000 | $4,000 |
| R&D expense | $227,000 | $388,000 | $427,000 | $361,000 | $469,000 | $185,000 | $347,000 | -$86,000 |
| SG&A expense | $533,000 | $564,000 | $585,000 | $549,000 | $718,000 | $854,000 | $747,000 | $845,000 |
| Operating income | -$760,000 | -$952,000 | -$1.01M | -$907,000 | -$1.19M | -$1.04M | -$1.09M | -$755,000 |
| Interest expense | — | — | — | — | — | — | — | $0 |
| Net income | -$772,000 | -$952,000 | -$1.01M | -$893,000 | -$1.16M | -$1.05M | -$1.07M | -$742,000 |
| EBITDA | -$752,000 | -$943,000 | -$1.00M | -$900,000 | -$1.19M | -$1.04M | -$1.09M | -$756,000 |
| EPS (basic) | -0.31 | -0.41 | -0.59 | — | -0.55 | -0.63 | -0.67 | — |
| EPS (diluted) | -0.31 | -0.41 | -0.59 | — | -0.55 | -0.63 | -0.67 | — |
| Weighted avg. shares (diluted) | 2.60M | 2.43M | 1.95M | — | 2.18M | 1.68M | 1.60M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $615,000 | $124,000 | $354,000 | $1.39M | $1.94M | $2.88M | $319,000 | $1.09M |
| Receivables | $0 | $0 | $0 | $3,000 | $0 | $2,000 | $2,000 | $5,000 |
| Current assets | $1.08M | $666,000 | $970,000 | $1.99M | $2.69M | $3.74M | $1.07M | $2.75M |
| PP&E, net | $66,000 | $74,000 | $82,000 | $91,000 | $97,000 | — | — | $0 |
| Total assets | $1.92M | $1.52M | $1.88M | $2.97M | $3.72M | $4.74M | $2.12M | $2.75M |
| Current liabilities | $947,000 | $864,000 | $595,000 | $813,000 | $921,000 | $1.07M | $1.06M | $692,000 |
| Long-term debt | — | — | — | — | — | — | — | $0 |
| Total debt | — | — | — | — | — | — | — | $0 |
| Total liabilities | $947,000 | $864,000 | $595,000 | $813,000 | $921,000 | $1.07M | $1.06M | $692,000 |
| Shareholders' equity | $971,000 | $652,000 | $1.29M | $2.15M | $2.80M | $3.66M | $1.06M | $2.06M |
| Net debt | — | — | — | — | — | — | — | -$1.09M |
| Shares outstanding | 3.32M | 2.49M | 2.38M | 2.35M | 2.21M | 2.07M | 1.60M | 1.60M |
| Cash flow statement | ||||||||
| Operating cash flow | -$425,000 | -$300,000 | -$1.03M | -$552,000 | -$844,000 | -$701,000 | -$772,000 | -$592,000 |
| Capital expenditure | — | — | — | $1,000 | — | — | — | $0 |
| Free cash flow | — | — | — | -$553,000 | — | — | — | -$592,000 |
| Investing cash flow | — | — | — | -$1,000 | — | — | — | $0 |
| Financing cash flow | $916,000 | — | — | $0 | $0 | — | — | $0 |
| Depreciation & amortization | $8,000 | $9,000 | $8,000 | $7,000 | $0 | $0 | $0 | -$1,000 |
| Stock-based compensation | $175,000 | $246,000 | $141,000 | $243,000 | $301,000 | $184,000 | $68,000 | $81,000 |
Free plan shows the latest 8 periods; Pro shows all 69 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.